Pushkal Garg
Evp Chief R&D at Alnylam Pharmaceuticals, Inc. (ALNY)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $8.1M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 10623,300 held (−0%) | $319.03 | $34K | -27.1% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 10223,198 held (−0%) | $320.01 | $33K | -27.3% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 21522,983 held (−1%) | $320.81 | $69K | -27.5% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 28922,694 held (−1%) | $321.82 | $93K | -27.7% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 35022,344 held (−2%) | $323.01 | $113K | -28.0% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 76721,577 held (−3%) | $323.84 | $248K | -28.1% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 27221,305 held (−1%) | $324.88 | $88K | -28.4% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 20821,097 held (−1%) | $325.67 | $68K | -28.6% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 65420,443 held (−3%) | $322.33 | $211K | -27.8% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 74019,703 held (−4%) | $323.55 | $239K | -28.1% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 51019,193 held (−3%) | $324.59 | $166K | -28.3% |
| Mar 6SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 50018,693 held (−3%) | $326.08 | $163K | -28.6% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 5026,848 held (−0%) | $323.62 | $16K | -28.1% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 9726,751 held (−0%) | $324.65 | $31K | -28.3% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 27726,474 held (−1%) | $325.63 | $90K | -28.5% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 42126,053 held (−2%) | $326.81 | $138K | -28.8% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 35325,700 held (−1%) | $327.67 | $116K | -29.0% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 10725,593 held (−0%) | $328.71 | $35K | -29.2% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 18225,411 held (−1%) | $329.71 | $60K | -29.4% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 8725,324 held (−0%) | $330.85 | $29K | -29.7% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 10125,223 held (−0%) | $331.93 | $34K | -29.9% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 4225,181 held (−0%) | $332.64 | $14K | -30.1% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 35524,826 held (−1%) | $316.74 | $112K | -26.5% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 31724,509 held (−1%) | $319.06 | $101K | -27.1% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 64023,869 held (−3%) | $320.48 | $205K | -27.4% |
| Mar 4SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 46323,406 held (−2%) | $321.50 | $149K | -27.6% |
| Mar 2SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 12726,629 held (−0%) | $328.92 | $42K | -29.3% |
| Mar 2SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 2,25924,370 held (−8%) | $330.73 | $747K | -29.6% |
| Mar 2SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 1,15923,211 held (−5%) | $331.49 | $384K | -29.8% |
| Mar 2SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 94222,269 held (−4%) | $332.48 | $313K | -30.0% |
| Mar 2SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 14022,129 held (−1%) | $334.39 | $47K | -30.4% |
| Feb 17SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 2,24224,848 held (−8%) | $310.08 | $695K | -25.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 3923,982 held (−0%) | $353.95 | $14K | -34.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4223,940 held (−0%) | $355.16 | $15K | -34.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4123,899 held (−0%) | $356.09 | $15K | -34.7% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 9623,803 held (−0%) | $357.17 | $34K | -34.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 12323,680 held (−1%) | $358.18 | $44K | -35.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 8523,595 held (−0%) | $359.14 | $31K | -35.2% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 15523,440 held (−1%) | $360.22 | $56K | -35.4% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 9823,342 held (−0%) | $361.45 | $35K | -35.6% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 7323,269 held (−0%) | $362.38 | $26K | -35.8% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4723,222 held (−0%) | $363.55 | $17K | -36.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 19923,023 held (−1%) | $364.83 | $73K | -36.2% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 22022,803 held (−1%) | $365.56 | $80K | -36.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 5022,753 held (−0%) | $366.41 | $18K | -36.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4122,712 held (−0%) | $367.40 | $15K | -36.7% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 9222,620 held (−0%) | $368.62 | $34K | -36.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 4022,580 held (−0%) | $369.48 | $15K | -37.0% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 1822,562 held (−0%) | $370.87 | $7K | -37.3% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 322,559 held (−0%) | $372.46 | $1K | -37.5% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 1422,545 held (−0%) | $374.44 | $5K | -37.9% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 1922,526 held (−0%) | $375.65 | $7K | -38.1% |
| Jan 14SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell | 1522,511 held (−0%) | $377.82 | $6K | -38.4% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 11526,065 held (−0%) | $446.53 | $51K | -47.9% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 5626,009 held (−0%) | $447.92 | $25K | -48.1% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 18025,829 held (−1%) | $448.77 | $81K | -48.2% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 24925,580 held (−1%) | $449.79 | $112K | -48.3% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 54125,039 held (−2%) | $450.81 | $244K | -48.4% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 33224,707 held (−1%) | $451.86 | $150K | -48.5% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 66824,039 held (−3%) | $452.69 | $302K | -48.6% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 32923,710 held (−1%) | $453.77 | $149K | -48.7% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 24423,466 held (−1%) | $454.84 | $111K | -48.8% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 7323,393 held (−0%) | $455.82 | $33K | -49.0% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 14723,246 held (−1%) | $457.43 | $67K | -49.1% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 323,243 held (−0%) | $457.64 | $1K | -49.2% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 68222,561 held (−3%) | $449.99 | $307K | -48.3% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 81021,751 held (−4%) | $450.63 | $365K | -48.4% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 89820,853 held (−4%) | $451.76 | $406K | -48.5% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 41720,436 held (−2%) | $453.51 | $189K | -48.7% |
| Oct 3SEC | ALNYAlnylam Pharmaceuticals, Inc. | Sell Plan | 21520,221 held (−1%) | $454.37 | $98K | -48.8% |
- Sell
Evp Chief R&D Pushkal Garg sold $34K of ALNY at $319.03 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp Chief R&D Pushkal Garg sold $33K of ALNY at $320.01 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp Chief R&D Pushkal Garg sold $69K of ALNY at $320.81 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp Chief R&D Pushkal Garg sold $93K of ALNY at $321.82 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp Chief R&D Pushkal Garg sold $113K of ALNY at $323.01 — pre-scheduled 10b5-1 plan sale.
- Sell
Evp Chief R&D Pushkal Garg sold $248K of ALNY at $323.84 — pre-scheduled 10b5-1 plan sale.